



UNITED STATES PATENT AND TRADEMARK OFFICE

[Signature]
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,274	07/07/2006	Hiroaki Yanagisawa	251371	9229

23460 7590 07/31/2007
LEYDIG VOIT & MAYER, LTD
TWO PRUDENTIAL PLAZA, SUITE 4900
180 NORTH STETSON AVENUE
CHICAGO, IL 60601-6731

EXAMINER

RAHMANI, NILOOFAR

ART UNIT	PAPER NUMBER
----------	--------------

1625

MAIL DATE	DELIVERY MODE
-----------	---------------

07/31/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/573,274

Applicant(s)

YANAGISAWA ET AL.

Examiner

Niloofer Rahmani

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 July 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15, 20, 21 and 26-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-15, 20, 21 and 26-35 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☒ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 1-15, 20-21, and 26-35 are currently pending in the instant application.

Claims 16-19, 22-25 are cancelled.

Priority

2. This application filed on 07/07/2006, which is a 371 of PCT/JP04/14684, filed on 09/29/2004, which claims priority of JAPAN 2003-340007, filed on 09/30/2003.

3. **Election/Restrictions**

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

I. Claims 1-4,6, 10, and 26-29 (in part), drawn to formula I, wherein **A** being (A1), **X** being C, and **B** being 1H-tetrazol-5-yl, classified in class 546, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

II. Claims 1-4,6, and 26-29, drawn to formula I, wherein **A** being (A1), **X** being O, and **B** being 1H-tetrazol-5-yl, classified in class 544, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

III. Claims 1-4,6,26-29 (in part), drawn to formula I, wherein **A** being (A1), **X** being S, and **B** being 1H-tetrazol-5-yl, classified in class 544, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

IV. Claims 1-4,6,26-29 (in part), drawn to formula I, wherein **A** being (A1), **X** being C, and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 546, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

V. Claims 1-4,6,26-29 (in part), drawn to formula I, wherein **A** being (A1), **X** being O, and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 546, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

VI. Claims 1-4,6,26-29 (in part), drawn to formula I, wherein **A** being (A1), **X** being S, and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 546, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

VII. Claims 1-4, and 26-29 (in part), drawn to formula I, wherein **A** being (A2), and **B** being 1H-tetrazol-5-yl, classified in class 546, subclass various. If this group is

Art Unit: 1625

elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

VIII. Claims 1,3-5,7, and 26-29 (in part), drawn to formula I, wherein **A** being (A2), and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 546, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

IX. Claims 1-4,8-11 and 26-29 (in part), drawn to formula I, wherein **A** being (A3), and **B** being 1H-tetrazol-5-yl, classified in class 548, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

X. Claims 1,3-5,8-11, and 26-29 (in part), drawn to formula I, wherein **A** being (A3), and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 549, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XI. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A1), **X** being C, and **B** being 1H-tetrazol-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XII. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A1), **X** being O, and

Art Unit: 1625

B being 1H-tetrazol-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XIII. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A1), **X** being S, and **B** being 1H-tetrazol-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XIV. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A1), **X** being C, and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XV. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A1), **X** being O, and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XVI. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A1), **X** being S, and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 514, subclass various. If this

Art Unit: 1625

group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XVII. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A2), and **B** being 1H-tetrazol-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XVIII. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A2), and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XIX. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A3), and **B** being 1H-tetrazol-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

XX. Claims 12-15, and 30-35, drawn to pharmaceutical composition and method for using the compound of formula (I), wherein **A** being (A3), and **B** being 2,4-dioxothiazolidin-5-yl, classified in class 514, subclass various. If this group is elected, a further election of a single disclosed species of compound is also required. Further restriction based on the species election may be required.

Art Unit: 1625

The inventions listed as Groups I-XX do not relate to a single general inventive concept under 35 USC 121 or PCT Rule 13.1 because:

PCT Rule 13.1 states that the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention").

PCT Rule 13.2 states that the unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

Annex B, **Part 1(a)**, indicates that the application should relate to only one invention, or if there is more than one invention, inclusion is permitted if they are so linked to form a single general inventive concept.

Annex B **Part 1(b)**, indicates that "special technical features" means those features that as a whole define a contribution over the prior art.

Annex B **Part 1(c)**, further defines independent and dependent claims. Unity of invention only is concerned in relation to independent claims. Dependent claims are defined as a claim that contains all the features of another claim and is in the same category as the other claim. The category of a claim refers to the classification of claims according to subject matter e.g. product, process, use, apparatus, means, etc.

Annex B **Part 1(e)**, indicates that the permissible combinations of different categories of claims. **Part 1(e)I**, states that inclusion of an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for a use of the said product is permissible.

Annex B, **Part 1(f)**, indicates the "Markush practice" of alternatives in a single claim.

Part 1(f)I, indicates the technical relationship and the same or corresponding special technical feature is considered to be met when (A) all alternatives have a common property or activity, and (B) a common structure is present or all alternatives belong to a recognized class of chemical compounds. Further defining (B), Annex B, **Part 1(f)I-iii**, the common structure must; a)

occupy a large portion of their structure, or b) the common structure constitutes a structurally distinctive portion, or c) where the structures are equivalent and therefore a recognized class of chemical compounds, each member could be substituted for one another with the same intended result. That is, with a common or equivalent structure, there is an expectation relationship and the corresponding special technical feature result from a common (or equivalent) structure that is responsible for the common activity (or property). **Part 1(f)iv**, indicates that when all alternatives of a Markush grouping can be differently classified, it shall not, taken alone, be considered justification for finding a lack of unity. **Part 1(f)v**, indicates that "When dealing with alternatives, if it can be shown that at least one Markush alternative is not novel over the prior art, the question of unity of invention shall be reconsidered by the examiner"

Art Unit: 1625

In the instant case, at least one Markush alternative is not novel because prior art by Kim et al., Korean Journal of Medicinal Chemistry, 1995, Vol. 5, pages 28-37 anticipated group I, thus the lacking of unity of invention has been found.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

NILOOFAR RAHMANI

07/23/2007

NR


D. MARGARET SEAMAN

PRIMARY EXAMINER

ART UNIT 1625